advanced gastric cancer
Conditions
Interventions
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18~80 years old; 2. Pathologically histology and/or cytological diagnosis with advanced gastric cancer; 3. Cytological diagnosis with malignant peritoneal effusion; 4. ECOG score: 0-2; 5. The expected survival more than three months; 6. The main organ function, that meet the following criteria: (1)subject to the standard blood test (14 days not blood transfusion and blood products): a.HB>=90 g/L; b.ANC>=1.5*10^9/L; c.PLT>=80*10^9/L; (2)biochemical tests must meet the following criteria: a.BIL 50 ml/min (Cockcroft-Gault formula); 7. The subjects voluntarily joined the study, informed consent, good compliance, with the follow-up.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating; 2. After suffering from high blood pressure and antihypertensive medications can not fall within the normal range (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg) above the level of suffering I coronary heart disease or arrhythmia (including QT interval of men>450 ms,women>470ms) and Class I cardiac insufficiency; urinary protein positive patients; 3. obvious factors of oral drug absorption, such as inability to swallow, nausea, emesis,chronic diarrhea and intestinal obstruction; 4. Patients with clear gastrointestinal bleeding concerns, including the following situations: local active ulcerative lesions, and defecate occult blood (++); black, hematemesis history within 2 months; for stool occult blood (+) and primary lesions without surgical removal of the stomach tumor, requirement of gastroscopy; such as ulcer type of gastric cancer, the digestive tract hemorrhage may occur; 5. Accompanied by the central nervous system transfer; 6. coagulation abnormalities (INR> 1.5 or APTT>1.5ULN + 4 seconds, or APTT>1.5 ULN), having bleeding tendency; 7. Have psychiatric history of drug abuse and can't quit, or have a mental disorder; 8. Participated in other drug clinical trials within four weeks; 9. Received the serous cavity puncture drainage treatment within a week; 10. Accepted the anti-angiogenesis therapy, such as sorafenib, sunitinib; 11. Serious to endanger the safety of patients or influence patients completed the research associated with disease; 12. Past and presenta, history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug related pneumonia, seriously damaged lung function with objective evidence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactChen Jia
Jiangsu Hengrui Medicine Co., Ltd.
Outcome results
None listed